Erik Thorsen, Chairman.
Mr. Thorsen (born 1956) holds a MBA from the University of Karlstad, Sweden. He was elected to the Board in 2011, and was elected chairman in 2013. Mr. Thorsen was the President and CEO of Renewable Energy Corporation ASA (REC) from 2005 till 2009, and the President and CEO of Tomra Systems ASA from 1996 till 2005. He is a strategic advisor to several companies, the Chairman of the Board of RenoNorden ASA, Metallkraft AS, Ålø AB and Northstar AB. Mr. Thorsen and close associates hold 23,500 shares in Biotec Pharmacon.
Inger Rydin, Director.
Ms. Rydin (born 1957) holds a Master of Science degree from Chalmers University of Technology, Sweden. Ms. Rydin was elected to the Board in 2014.
Her latest assignments have been as CEO of entrepreneurial companies in the Life Science and Health Care industry. Before this she was serving as VP Wound & Skin Care Global Marketing of Coloplast and Managing Director of the Mölnlycke Health Care subsidiary in Eastern Europe. Ms. Rydin started her career in SCA Hygiene /Mölnlycke in 1981 in Research & Development and has held a range of management positions in Marketing & Sales. Rydin holds no shares in Biotec Pharmacon.
Masha P.N. Le Gris Strømme, Director.
Masha P.N. Le Gris Strømme (44) holds a Ph.D in Genetics and Neuroscience from Oxford University in England. Strømme has experience from investment banking in Morgan Stanley and Altium Capital focusing on Life Science. She has extensive board experience through several board positions. Ms Strømme holds no shares in Biotec Pharmacon.
Olav Flaten, Director.
Mr. Flaten (born 1946) holds a PhD (dr. med.) from University of Oslo. He was elected to the Board in 2013. Mr. Flaten has served as Medical Director in Alpharma, and in Glaxo, Glaxo Wellcome, GlaxoSmithKline. He has also been Chairman of R&D committee in Norwegian Association of Pharmaceutical Industries (LMI), and member of the Trade Policy Committee of LMI. Mr. Flaten has since 2010 been Board member of NRInetworks. Presently he is also Project manager for a Nordic research project funded by the Nordic Council of Ministers (Nordic Innovation). Mr. Flaten holds no shares or options in Biotec Pharmacon.
Richard S. Godfrey, Director.
Mr. Godfrey (born 19xx) is the CEO of BerGenBio AS. Mr Godfrey was elected to the Board in 2016.
He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles.He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. Mr Godfrey has no shares in Biotec Pharmacon.
Gerd Nilsen, Director, Employee representative.
Ms. Nilsen (born 1968) holds a M.Sc. and a Dr.Scient. from the University of Tromsø, and an MBA from University of Nordland. Nilsen joined Biotec Pharmacon in 2004 as Product manager for marine enzymes. Since 2010 she has been Head of product management in ArcticZymes, a Biotec Pharmacon subsidiary, and from 2011 Head of customer Operations in ArcticZymes. Nilsen is Member of the Board since 2013. Number of shares in Biotec Pharmacon held by Dr. Nilsen: 26,190. Number of options: 51,000.